Four weeks ago, after a Houston judge denied J&J’s third attempt to resolve approximately 90,000 talcum powder lawsuits ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

While it was generally assumed that the return to power of business-friendly President Donald Trump would help facilitate M&A ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

Far from doffing their caps to actinic keratosis (AK), dermatology drug developers Almirall and Biofrontera are keeping ...